BrightGene Phase III Data for BGM0504 Highlight Multi-Parameter Metabolic Effects

BrightGene Bio-Medical disclosed Phase III clinical data for BGM0504 as competition in the weight loss drug market progressively intensifies. Mean weight reduction was 19.3%, waist circumference decreased 16.5 cm, and systolic blood pressure fell 22.9 mmHg in the hypertensive population, alongside uric acid reduction of 70.7 μmol/L, triglyceride reduction of 33.6%, bone mineral density showing improvement rather than decline despite weight loss, and a discontinuation rate of 0.7% in the high-dose group.

The data showed coordinated improvement across multiple endpoints rather than a breakthrough in any single metric. A 16.5 cm reduction in waist circumference suggests a direct impact on visceral fat, while a blood pressure reduction of more than 20 mmHg, together with a target achievement rate above 90%, moves the effect from ancillary improvement into a clinically actionable range. A 70.7 μmol/L decrease in uric acid and a triglyceride reduction of more than 30% are approaching the magnitude typically seen with dedicated metabolic therapies.

In the context of nearly 20% weight loss, bone mineral density did not decline but instead increased, while the discontinuation rate remained at a low 0.7%. This indicates that improved efficacy was not achieved at the expense of bone loss or reduced treatment adherence. When a single drug can simultaneously improve body weight, blood pressure, blood lipids and uric acid, it demonstrates effects across multiple chronic disease populations.

The company said a target previously regarded largely as a supporting player is now entering the core spotlight: GIP. Within the GLP-1 pathway, weight loss primarily stems from intake control, achieved via appetite suppression and delayed gastric emptying, while improvements in blood pressure, lipid profile, and other markers are largely secondary consequences of weight reduction. In contrast, GIP acts more as an intrinsic regulatory variable within the metabolic system.

The GIP receptor is highly expressed in adipose tissue. Upon activation, it modulates adipose tissue blood flow and inflammatory status, thereby regulating fat distribution. This process not only affects body fat percentage but also drives coordinated improvements across multiple parameters, including blood lipids and blood pressure, by enhancing insulin sensitivity.

From the Phase III data of BGM0504, a clear correlation can be observed with this mechanistic pathway. A 33.6% decrease in triglycerides, along with reduced LDL-C and elevated HDL-C, demonstrates favorable remodeling of lipid metabolism. For blood pressure, multiple factors act in concert, including reduced adipose inflammation, improved insulin resistance, and enhanced vascular endothelial function, leading to a systolic blood pressure reduction of over 22.9 mmHg and a 92.9% control rate.